Squarepoint Ops LLC Raises Holdings in Kymera Therapeutics, Inc. $KYMR

Posted by Stanley Muller on Sep 10th, 2026

Squarepoint Ops LLC lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 657.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 97,189 shares of the company’s stock after purchasing an additional 84,350 shares during the period. Squarepoint Ops LLC owned about 0.12% of Kymera Therapeutics worth $11,145,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. California State Teachers Retirement System grew its stake in Kymera Therapeutics by 10,989.5% during the 2nd quarter. California State Teachers Retirement System now owns 6,241,373 shares of the company’s stock worth $715,698,000 after buying an additional 6,185,091 shares during the last quarter. BlackRock Inc. purchased a new stake in Kymera Therapeutics in the second quarter valued at approximately $635,067,000. Baker BROS. Advisors LP lifted its stake in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after buying an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after acquiring an additional 1,124,747 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after acquiring an additional 1,061,957 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Bank of America lifted their target price on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Morgan Stanley reiterated an “overweight” rating and set a $135.00 price target on shares of Kymera Therapeutics in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Friday, July 17th. Canaccord Genuity Group upped their target price on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a report on Friday, June 26th. Finally, Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a research note on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $128.70.

Check Out Our Latest Research Report on Kymera Therapeutics

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $115.43 on Thursday. The stock has a market capitalization of $9.60 billion, a P/E ratio of -35.63 and a beta of 1.96. The company’s fifty day moving average is $114.38 and its two-hundred day moving average is $95.64. Kymera Therapeutics, Inc. has a 1 year low of $42.71 and a 1 year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company had revenue of $65.00 million during the quarter, compared to analysts’ expectations of $32.78 million. During the same quarter last year, the business earned ($0.95) EPS. The business’s revenue was up 465.2% on a year-over-year basis. Sell-side analysts predict that Kymera Therapeutics, Inc. will post -3.83 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 31,283 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $109.48, for a total value of $3,424,862.84. Following the sale, the director owned 461,794 shares of the company’s stock, valued at approximately $50,557,207.12. The trade was a 6.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $119.00, for a total value of $5,950,000.00. Following the transaction, the chief executive officer owned 666,568 shares in the company, valued at $79,321,592. The trade was a 6.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,594,000 shares of company stock valued at $386,928,106 over the last 90 days. Insiders own 15.98% of the company’s stock.

Kymera Therapeutics Profile

(Free Report)

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.